| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,694,057 | 6 | 100 |
| Ogden Christopher | Chief Financial Officer | 0 | $0 | 2 | $129,065 | $-129,065 |
| Chu Yu-Waye | Chief Medical Officer | 0 | $0 | 1 | $136,675 | $-136,675 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 0 | $0 | 1 | $202,273 | $-202,273 |
| McCarthy Sean A. | CEO | 0 | $0 | 2 | $1.23M | $-1.23M |
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II …
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $1.69M worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $452,873 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
| 2026-06-15 | Sale | Ogden Christopher | Chief Financial Officer | 1,624 0.001% | $3.05 | $4,953 | +7.24% | |
| 2026-03-17 | Sale | McCarthy Sean A. | CEO | 118,969 0.0828% | $6.42 | $764,138 | -37.25% | |
| 2026-03-17 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 31,492 0.0219% | $6.42 | $202,273 | -37.25% | |
| 2026-03-17 | Sale | Ogden Christopher | Chief Financial Officer | 19,323 0.0134% | $6.42 | $124,112 | -37.25% | |
| 2026-03-17 | Sale | Chu Yu-Waye | Chief Medical Officer | 21,279 0.0148% | $6.42 | $136,675 | -37.25% | |
| 2025-11-06 | Sale | McCarthy Sean A. | CEO | 101,793 0.0785% | $4.54 | $461,906 | -8.71% | |
| 2025-06-16 | Sale | McCarthy Sean A. | CEO | 55,511 0.0385% | $2.69 | $149,264 | +54.88% | |
| 2025-06-16 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 13,884 0.0096% | $2.69 | $37,334 | +54.88% | |
| 2025-06-16 | Sale | Ogden Christopher | Chief Financial Officer | 10,614 0.0074% | $2.69 | $28,540 | +54.88% | |
| 2025-06-13 | Sale | Ogden Christopher | Chief Financial Officer | 1,641 0.0011% | $2.95 | $4,841 | +39.45% | |
| 2025-03-18 | Sale | McCarthy Sean A. | CEO | 37,656 0.0466% | $0.60 | $22,556 | +338.96% | |
| 2025-03-18 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 19,512 0.0242% | $0.60 | $11,688 | +338.96% | |
| 2025-03-18 | Sale | Ogden Christopher | Chief Financial Officer | 8,551 0.0106% | $0.60 | $5,122 | +338.96% | |
| 2025-03-18 | Sale | Chu Yu-Waye | Chief Medical Officer | 4,025 0.005% | $0.60 | $2,411 | +338.96% | |
| 2025-03-18 | Sale | ROWLAND LLOYD A | General Counsel | 10,203 0.0126% | $0.60 | $6,112 | +338.96% | |
| 2024-08-20 | Sale | McCarthy Sean A. | CEO | 13,898 0.0176% | $1.23 | $17,082 | -10.08% | |
| 2024-08-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | Ogden Christopher | Chief Financial Officer | 1,984 0.0025% | $1.23 | $2,439 | -10.08% |
| Flynn James E | 10 percent owner | 671024 0.308% | $1.46M | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.1247% | $592,181.74 | 1 | 8 | <0.0001% |
| ROWLAND LLOYD A | General Counsel | 120594 0.0553% | $262,894.92 | 1 | 7 | <0.0001% |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0064% | $30,339.06 | 1 | 1 | <0.0001% |
| Jones Elaine V | director | 5142 0.0024% | $11,209.56 | 1 | 0 | +0.98% |
| LADD CYNTHIA J | Senior VP and General Counsel | 3000 0.0014% | $6,540.00 | 1 | 0 | <0.0001% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$31,271,604 | 28 | 28.69% | $477.19M |
| Increased Positions | 78 | +71.56% | 38M | +27.75% |
| Decreased Positions | 45 | -41.28% | 31M | -22.92% |
| New Positions | 39 | New | 7M | New |
| Sold Out Positions | 20 | Sold Out | 21M | Sold Out |
| Total Postitions | 142 | +30.28% | 144M | +4.83% |
| Vr Adviser, Llc | $66,136.00 | 9.21% | 15.56M | +2M | +11.39% | 2025-09-30 |
| Fmr Llc | $65,434.00 | 9.11% | 15.4M | +6M | +66.65% | 2025-09-30 |
| Tang Capital Management Llc | $47,029.00 | 6.55% | 11.07M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $41,141.00 | 5.73% | 9.68M | +3M | +38.41% | 2025-09-30 |
| Vanguard Group Inc | $38,028.00 | 5.3% | 8.95M | -431,987 | -4.61% | 2025-09-30 |
| Orbimed Advisors Llc | $35,961.00 | 5.01% | 8.46M | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $32,692.00 | 4.55% | 7.69M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $18,066.00 | 2.52% | 4.25M | +766,600 | +22% | 2025-09-30 |
| Point72 Asset Management, L.P. | $17,291.00 | 2.41% | 4.07M | -4M | -49.67% | 2025-09-30 |
| Adar1 Capital Management, Llc | $17,193.00 | 2.39% | 4.05M | +964,000 | +31.28% | 2025-09-30 |